Public Release: 

Molecular flexibility shown to help pharmaceutical drugs bind to their targets



IMAGE: Scientists have discovered an alternative way to create a stronger binding between pharmaceutical drugs and the part of the body they are targeting -- a development that can be used... view more

Credit: Fabio Hofnik / Flickr

Scientists have discovered an alternative way to create a stronger binding between pharmaceutical drugs and the part of the body they are targeting - a development that can be used to fight a variety of diseases, including breast cancer. The study published in PLOS Computational Biology shows that flexible molecules, instead of rigid ones, as previously thought, can bind more effectively to the proteins causing the disease.

Being a tight binder is important for a molecule to be a good pharmaceutical drug. When designing a pharmaceutical drug, scientists typically make molecules - which are naturally flexible - rigid so that they can strongly bind, like a lock and key, with the disease causing protein in the body.

When molecules bind to their partners they usually decrease their flexibility which leads to the so-called entropy penalty. Having a large entropy penalty has been shown to be bad for creating a tight bindings. Scientists aim to reduce it so that the drug can stay on the target protein and alter its functional behavior for good. However, one key problem to this approach is that scientists are reaching the limit of how much rigidity can be produced in order to reduce entropy penalty and result in tighter binders.

Researchers, led by Wanli You (University of California), found that keeping the molecules flexible, as opposed to making them rigid, both reduced the entropy penalty and created a stronger binding. One of the authors, Chia-en A. Chang, notes that "This was really unexpected and opens up a new direction for designing pharmaceutical drugs".

In order to discover this, the researchers examined the thermodynamic properties of different ligands binding to a promiscuous modular protein, Breast-cancer-gene 1 (BRCA1) C-terminal (BRCT). The authors used molecular dynamics simulations and a rigorous free energy calculation method to study ligands binding to BRCT, understand promiscuous molecular recognition and guide inhibitor design. Flexible ligands, the researchers found, may utilize multiple conformations in their bound states to keep good attractions with BRCT whilst also reducing entropy cost.

The research focused on breast cancer drugs, but the principles could be applied in drug development targeting other diseases and also in basic cell biology studies.


In your coverage please use this URL to provide access to the freely available article in PLOS Computational Biology:

Contact: Name: Chia-en A. Chang

Citation: You W, Huang Y-mM, Kizhake S, Natarajan A, Chang C-eA (2016) Characterization of Promiscuous Binding of Phosphor Ligands to Breast-Cancer-Gene 1 (BRCA1) C-Terminal (BRCT): Molecular Dynamics, Free Energy, Entropy and Inhibitor Design. PLoS Comput Biol 12(8): e1005057. doi:10.1371/journal.pcbi.1005057

Image Caption: Molecular flexibility Shown to Help Pharmaceutical Drugs Bind to Their Targets

Image Credit: Fabio Hofnik / Flickr

Image Link:

Funding: This research was supported by the US National Institutes of Health (GM109045) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

About PLOS Computational Biology

PLOS Computational Biology features works of exceptional significance that further our understanding of living systems at all scales through the application of computational methods. For more information follow @PLOSCompBiol on Twitter or contact

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.